Oral Tirzepatide — The Future of Weight Loss Pills - The Compounding Catastrophe

Oral Tirzepatide — Discover the future of weight loss with Dr. Ben Synth

Join Dr. Ben Synth as he investigates the high-stakes race to transform injectable weight loss drugs like tirzepatide into a pill—exploring the groundbreaking science of shrinking massive molecules, the potential to democratize obesity treatment for billions, and the dangerous shortcuts emerging as desperation outpaces safety. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Oral Tirzepatide — The Future of Weight Loss Pills - The Compounding Catastrophe

Ben Synth examines how tirzepatide shortages drove desperate patients to unregulated compounding pharmacies offering untested oral versions, resulting in over 300 adverse events. The episode explores the collision between pharmaceutical innovation, regulatory gaps, and a healthcare system struggling to meet demand for breakthrough weight-loss treatments. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Oral Tirzepatide — The Future of Weight Loss Pills - A Pill for the World

Ben Synth explores orforglipron, Eli Lilly's daily oral weight loss pill showing 27-pound average loss in Phase 3 trials. Unlike injectable alternatives requiring refrigeration and needles, this room-temperature tablet could revolutionize global obesity treatment by reaching underserved populations. We examine clinical data, access barriers, and why slightly reduced efficacy at massive scale beats maximum results for privileged few. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Oral Tirzepatide — The Future of Weight Loss Pills - The Molecule That Could Kill the Needle

Ben Synth explores orforglipron, Eli Lilly's experimental oral weight-loss pill showing 27.3 pounds average loss in trials. Unlike injectable tirzepatide, this small-molecule GLP-1 agonist requires no refrigeration or needles, potentially reaching global populations where injectables fail—if FDA approval comes through in 2026. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.